Description
new trends IN COSMETICS
Tranexamic acid for the treatment of melasma, clinical evidences and mechanism of action
Javier fidalgo – PhD, scientific researcher
Tranexamic acid (TXA) can be successfully and safely used in the treatment of melasma by reducing epidermal melanin pigmentation, micro-vascularization presence in melasma lesions, and must cell count resulting in significant reduction in Melasma Severity Index (MASI) score. The molecular targets for TXA are the inhibition of plasmin activity, thus, lowering the levels of α-melanocyte-stimulating hormone by keratinocytes, diminishing the active forms of the vascular endothelial growth factor, and reducing the production of melanocyte stimulating factor endothelin-1. TXA was confirmed to be superior to hydroquinone at 4 weeks and comparable to it at 20 weeks after treatment…
FULL TEXT ARTICLE (Purchase PDF):
1,50€Add to cart
